StockTipsArenaBeta

BUY Aurobindo Pharma — Ajit Mishra, Religare

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byAjit Mishra, ReligareHorizon: NA (inferred Swing (≤2wk))10 Jun 2026via ET Now

Entry₹1,430Stated
Target₹1,530
Total upside +6.99% (call closed)
Stop lossNot given
Exit₹1,53023 Jun 2026, 12:15 pm
Target hit+6.99%0.00%upside left
Follow Ajit Mishra for new calls(22% target hit, 114 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 12:03 am IST
6 supporting0 opposing
Supports the BUY call (6)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·23 Jun · today

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · yesterday

(opens in new tab)

Aurobindo Pharma USA, a subsidiary of Aurobindo Pharma Ltd, has received FTC approval to acquire Lannett Company LLC for $250 million. This acquisition is expected to be immediately accretive to earni

BSE · Company Update·22 Jun · yesterday

(opens in new tab)

Aurobindo Pharma Ltd has received final US FDA approval for its Tafacitinib tablets in 5 mg and 10 mg strengths. This approval is a significant regulatory milestone for the company's pharmaceutical pr

BSE · Company Update·4 Jun · 3w ago

(opens in new tab)

Aurobindo Pharma Ltd is issuing a press release regarding the inauguration of Theranym, a large-scale biologics contract manufacturing facility in India.

BSE · Company Update·3 Jun · 3w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Ajit Mishra, Religare

Every call and its outcome